Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Weifuchun Tablet in Reversing Gastric Intestinal Metaplasia
NCT06610266Phase 4Recruiting
- Sponsor
- Yongquan Shi
- Start
- Feb 2025
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of weifuchun in gastric intestinal metaplasia (IM) (2 arms), sponsored by Yongquan Shi. Primary endpoints: The regression rate of gastric intestinal metaplasia based on OLGIM stage at 6 months and The progression rate of gastric intestinal metaplasia based on OLGIM stage at 6 months. Started Feb 2025; status: recruiting.
02
Drugs
weifuchun
03
Conditions
gastric intestinal metaplasia (IM)
Beyond the preview
Go deeper on NCT06610266.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06610266.